Literature DB >> 15609410

Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-alpha.

Chun-Song Wu1, Xi-Xu Piao, Dong-Ming Piao, Yong-Ri Jin, Cheng-Hao Li.   

Abstract

AIM: To investigate the effect of Boschniakia rossica (BR), oxymatrine (OM) and interferon-alpha (IFN-alpha) 1b on the therapy of rat liver fibrosis and its mechanism.
METHODS: By establishing a rat model of pig serum-induced liver fibrosis, liver/weight index and serum alanine transaminase (ALT) were observed to investigate the therapeutic effect of BR,OM and IFN-alpha. Radioimmunoassay was utilized to measure procollagen type III (PCIII) and collagen type IV (CIV). RT-PCR was used to assay the expression of liver transforming growth factor-beta 1 (TGF-beta1) mRNA. Immunohistochemistry of alpha-smooth muscle actin (alpha-SMA) and pathologic changes of liver tissues were also under investigation.
RESULTS: Serum PCIII and CIV in BR, OM and IFN-alpha groups were significantly declined compared with those in model group, and their RT-PCR revealed that TGF-beta1 mRNA expression was also reduced more than that in model group. Immunohistochemistry demonstrated that alpha-SMA also declined more than that in model group. Serum ALT in IFN-alpha, control and model groups was within normal level. Serum ALT in BR group had no significant difference from those of IFN-alpha, control and model groups. Serum ALT in OM group was significantly higher than those in BR, IFN-alpha, model, and control groups.
CONCLUSION: BR, OM and IFN-alpha can prevent pig serum-induced liver rat fibrosis by inhibiting the activation of hepatic stellate cells and synthesizing collagen. OM has hepatotoxicity to rat liver fibrosis induced by pig serum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15609410      PMCID: PMC4205370          DOI: 10.3748/wjg.v11.i1.122

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  Interferon-alpha enhances biological defense activities against oxidative stress in cultured rat hepatocytes and hepatic stellate cells.

Authors:  Guangming Lu; Ichiro Shimizu; Xuezhi Cui; Mina Itonaga; Katsuyoshi Tamaki; Hiroshi Fukuno; Hiroshi Inoue; Hirohito Honda; Susumu Ito
Journal:  J Med Invest       Date:  2002-08

2.  Effect of Boschniakia rossica on expression of GST-P, p53 and p21(ras)proteins in early stage of chemical hepatocarcinogenesis and its anti-inflammatory activities in rats.

Authors:  Zong-Zhu Yin; Hai-Ling Jin; Xue-Zhe Yin; Tian-Zhu Li; Ji-Shu Quan; Zeng-Nan Jin
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.

Authors:  L Mazzoran; G Tamaro; M A Mangiarotti; P Marchi; S Baracetti; U Gerini; M Fanni-Cannelles; F Zorat; G Pozzato
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-02       Impact factor: 2.566

4.  Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo.

Authors:  I Sakaida; K Uchida; Y Matsumura; K Okita
Journal:  J Hepatol       Date:  1998-03       Impact factor: 25.083

5.  Radical scavenger effect of Boschniakia rossica.

Authors:  T Tsuda; A Sugaya; Y Z Liu; K Katoh; H Tanaka; H Kawazura; E Sugaya; M Kusai; M Kohno
Journal:  J Ethnopharmacol       Date:  1994-01       Impact factor: 4.360

6.  Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment.

Authors:  K Jármay; M Gallai; G Karácsony; Z Ozsvár; Z Schaff; J Lonovics; I Kovalszky
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

7.  Iridoid compounds from Boschniakia rossica.

Authors:  Z Z Yin; H S Kim; Y H Kim; J J Lee
Journal:  Arch Pharm Res       Date:  1999-02       Impact factor: 4.946

8.  [Effect of Boschniakia rossica extract on antioxidative activities in rat hepatic preneoplasia induced by diethylnitrosamine].

Authors:  M Shen; Z Yin
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  1999-12

9.  Effect of alpha-interferon on erythrocyte and hepatocyte plasma membranes derived from cirrhotic rats.

Authors:  P Muriel; J Bolaños; J M Barral; G Torres
Journal:  Pharmacology       Date:  1994-01       Impact factor: 2.547

10.  Reinforcement effects of Boschniakia rossica on discrimination learning in cholinergic lesions of rats.

Authors:  T Tusda; Y Z Liu; A Sugaya; K Katoh; K Hori; S Tanaka; M Nomura; E Sugaya
Journal:  J Ethnopharmacol       Date:  1994-10       Impact factor: 4.360

View more
  6 in total

1.  Synergistic effect of a novel oxymatrine-baicalin combination against hepatitis B virus replication, alpha smooth muscle actin expression and type I collagen synthesis in vitro.

Authors:  Yang Cheng; Jian Ping; Huai-Dong Xu; Hai-Jun Fu; Zhao-Hui Zhou
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

2.  Effect of oxymatrine on hepatic gene expression profile in experimental liver fibrosis of rats.

Authors:  Yi-cheng Jian; Wei Li; Yi He; Ming Jiang; Yan-bing Liu; Wu-jun Xiong
Journal:  Chin J Integr Med       Date:  2012-07-22       Impact factor: 1.978

Review 3.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 4.  Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?

Authors:  Yau-Tuen Chan; Ning Wang; Hor Yue Tan; Sha Li; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

5.  Oxymatrine Protects TGFβ1-Induced Retinal Fibrosis in an Animal Model of Glaucoma.

Authors:  Ashmita Das; Onkar Kashyap; Amrita Singh; Jaya Shree; Kamta P Namdeo; Surendra H Bodakhe
Journal:  Front Med (Lausanne)       Date:  2022-02-18

6.  Plumbagin Ameliorates CCl 4 -Induced Hepatic Fibrosis in Rats via the Epidermal Growth Factor Receptor Signaling Pathway.

Authors:  Si Chen; Yi Chen; Bi Chen; Yi-Jing Cai; Zhuo-Lin Zou; Jin-Guo Wang; Zhuo Lin; Xiao-Dong Wang; Li-Yun Fu; Yao-Ren Hu; Yong-Ping Chen; Da-Zhi Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-15       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.